{"id":"NCT02720523","sponsor":"AbbVie","briefTitle":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs","officialTitle":"A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-03-22","primaryCompletion":"2017-08-03","completion":"2022-06-07","firstPosted":"2016-03-28","resultsPosted":"2019-10-21","lastUpdate":"2023-06-07"},"enrollment":197,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Upadacitinib","otherNames":["ABT-494","RINVOQâ„¢"]}],"arms":[{"label":"Placebo / Upadacitinib 7.5 mg","type":"EXPERIMENTAL"},{"label":"Placebo / Upadacitinib 15 mg","type":"EXPERIMENTAL"},{"label":"Placebo / Upadacitinib 30 mg","type":"EXPERIMENTAL"},{"label":"Upadacitinib 7.5 mg / Upadacitinib 7.5 mg","type":"EXPERIMENTAL"},{"label":"Upadacitinib 15 mg / Upadacitinib 15 mg","type":"EXPERIMENTAL"},{"label":"Upadacitinib 30 mg / Upadacitinib 30 mg","type":"EXPERIMENTAL"}],"summary":"This is a randomized, double-blind study comparing ABT-494 to placebo in Japanese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and have an inadequate response.\n\nFollowing marketing approval of upadacitinib for rheumatoid arthritis in Japan, this study will become a post-marketing clinical study and include a long-term extension period.","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":42.9,"sd":null},{"arm":"Upadacitinib 7.5 mg","deltaMin":75.5,"sd":null},{"arm":"Upadacitinib 15 mg","deltaMin":83.7,"sd":null},{"arm":"Upadacitinib 30 mg","deltaMin":80,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG001 vs OG002 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":50,"countries":["Japan"]},"refs":{"pmids":["32277824","34041702","33407801"],"seeAlso":["https://www.abbvieclinicaltrials.com/study/?id=M14-663#additional-resources-section"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":49},"commonTop":["Nasopharyngitis","Stomatitis","Herpes zoster","Influenza","Constipation"]}}